Ignite Creation Date:
2025-12-24 @ 10:52 PM
Ignite Modification Date:
2026-04-09 @ 8:53 AM
Study NCT ID:
NCT05869669
Status:
COMPLETED
Last Update Posted:
2025-07-18
First Post:
2023-04-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Sponsor:
EIP Pharma Inc
Organization:
Study Overview
Official Title:
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies
Status:
COMPLETED
Status Verified Date:
2025-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| R01AG080536 | NIH | None | https://reporter.nih.gov/quic… | View |
| 2023-504373-20 | EUDRACT_NUMBER | None | View |